ClearSight Therapeutics Receives NIH SBIR Phase I Award for Conjunctivitis and EKC Research
Sep 22, 2026
DALLAS - Sept. 22, 2026 - PRLog -- ClearSight Therapeutics, Inc. Receives NIH SBIR Phase I Award for Research in Acute Infectious Conjunctivitis and EKC
Competitive federal award provides external scientific validation of the proposed research program and funds a disciplined path to new evidence
DALLAS, September 22nd, 2026 - ClearSight Therapeutics, Inc., a Dallas-based eye-care company, today announced that it has received a $306,852 Small Business Innovation Research Phase I award from the National Eye Institute, part of the National Institutes of Health. The competitive award marks a major scientific milestone for ClearSight and supports a one-year investigational research program involving a preservative-free ophthalmic formulation in acute infectious conjunctivitis and epidemic keratoconjunctivitis.
The project, award number R43EY039140, runs from September 15, 2026 through August 31, 2027. ClearSight Chief Scientific Officer Nuria Jimenez, PhD, PMP, will serve as principal investigator. The Notice of Award identifies the project as research and development and states that it does not support an NIH-defined clinical trial.
Why this award matters
NIH funding decisions follow rigorous peer review of scientific and technical merit and a second-level assessment of mission relevance. Reviewers consider the importance of the proposed research, the rigor and feasibility of the approach, and whether the investigators and organization have the expertise and resources to carry out the work. For ClearSight, the award provides meaningful external validation of the proposed scientific program and creates an accountable path for turning a promising research premise into credible evidence. It does not predetermine the results; it makes the disciplined work to generate those results possible.
"This award is a defining milestone for ClearSight. Following competitive review of the scientific and technical merit of our proposed work, NIH support gives us both meaningful external validation and non-dilutive capital to build the evidence base with rigor. It is a powerful vote of confidence in the importance of the question, the strength of the research plan, and our team's ability to execute."
Patrick Smale, Co-founder and Chief Executive Officer
"The questions at the center of this program matter to patients, clinicians, and the broader eye-care community. NIH support gives us the opportunity to investigate them with the rigor they deserve, generate credible data, and let the evidence guide what comes next. I am proud to lead this work alongside our team and collaborators."
Nuria Jimenez, PhD, PMP, Chief Scientific Officer and Principal Investigator
"I am excited and grateful for this initial support from the National Eye Institute, which represents an important step in advancing our innovation toward clinical development. This funding will enable us to generate the rigorous data needed to further validate the technology and its potential to address important unmet needs in topical ocular therapy. As a co-inventor and drug developer, I am particularly encouraged by the opportunity to translate this innovation into a product where patient safety, efficacy, and meaningful clinical benefit remain our highest priorities."
Suchismita Acharya, PhD, Co-Founder, Co-Inventor and Board Member
The SBIR program supports research and development by eligible small businesses. Beyond providing non-dilutive capital, the award gives ClearSight a structured milestone period through August 2027 and an accountable framework for translating a scientific premise into data. The work will proceed under a defined research plan, milestones, and federal reporting obligations.
Important regulatory context
ClearSight's NIH-funded research program will study preservative-free ophthalmic formulation in acute infectious conjunctivitis and EKC. This investigational research is separate from the labeled uses of any OTC lubricant eye drop marketed under M018 and does not establish safety, efficacy, or regulatory approval for treating either condition.
About ClearSight Therapeutics
ClearSight Therapeutics is a Dallas-based eye-care company founded in 2023 by industry veterans to develop accessible solutions for common ocular conditions. The company maintains distinct commercial and research programs, including OTC lubricant development under applicable monograph labeling and separately described investigational research. Learn more at clearsighttx.com.
NIH funding acknowledgment
Research reported in this release is supported by the National Eye Institute of the National Institutes of Health under Award Number R43EY039140. A total of $306,852, or 100% of the project, is financed with federal funds. A total of $0, or 0%, is financed with non-governmental funds. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Media contact
Patrick Smale
Co-founder & CEO
ClearSight Therapeutics
[email protected]
972-983-7761
Photos: (Click photo to enlarge)
Source: ClearSight Therapeutics, Inc.
Read Full Story - ClearSight Therapeutics Receives NIH SBIR Phase I Award for Conjunctivitis and EKC Research | More news from this source
Press release distribution by PRLog
More News
Paramount Shares Tick Up After Settlement As Wall Street Remains Cautiously Optimistic About WBD Merger
A day after the stunning news of an antitrust legal settlement clearing Paramount’s path to close a landmark merger, the company’s stock ticked up 2% amid cautious Wall Street optimism. Shares in Paramount ended Tuesday’s trading at $10.11, down almost 25% in 2026 to date. The stock slumped late in the day Monday despite the […]
Mary Beth Barone Shuts Down Joe Alwyn Romance Rumors With One Post
Mary Beth Barone was only having conversations with a friend. Less than a week after sparking romance speculation with Joe Alwyn, the Overcompensating actress set the record straight with one...
A Pablo Pledgescobar series is already in the works
The dust hasn't even settled on the Penn State cocaine bust, but Netflix is developing a comedy about it.
Protesters at Paramount's gates say Bonta 'caved' on Warner Bros. merger deal
Dozens rallied outside Paramount's Hollywood lot, saying the settlement clearing its Warner Bros. merger fails to protect L.A. entertainment jobs.
Is ‘Primetime’ Based on a True Story? Robert Pattinson’s Chris Hansen Movie Explained
Robert Pattinson is taking on the role of controversial television figure Chris Hansen in the upcoming A24 film Primetime, following […] The post Is ‘Primetime’ Based on a True Story? Robert Pattinson’s Chris Hansen Movie Explained appeared first on Just Jared - Celebrity News, Entertainment News & Photos.
All the Top Shows, Movies and Networks in the Merged Paramount-Warner Bros: ‘Yellowstone,’ ‘Harry Potter,’ ‘Mission: Impossible’ and DC Under One Roof
In line with mega-mergers that have come before, the impending marriage of Paramount Skydance and Warner Bros. Discovery will lead to a media company packed with assets. What differentiates this deal — which is now in the clear to move forward — from others is the sheer amount of brands and intellectual property in play. […]
Streamer Subscription Prices And Tiers – Everything To Know As Costs Rise And Ads Abound
Peacock and Apple TV are the latest platforms to raise their streaming subscription prices over the summer. Netflix raised pricing for all its subscription tiers as of the end of March 2026. The new pricing bumped the fee to $8.99 a month for Netflix’s Standard with Ads tier, up $1. The standard tier now costs […]
Focus Features Closing In On ‘Romeo And Juliet’ Adaptation From Robert Eggers
Robert Eggers, the filmmaker behind Nosferatu and the upcoming Werwulf, is eyeing a return to Focus Features with a new take on William Shakespeare’s Romeo and Juliet that has been competitively sought after, Deadline has confirmed. Details as to Eggers’ take are under wraps. His deal is not yet finalized, but we understand he’ll direct […]
‘60 Minutes’ Notches Ratings Gain Over Last Year, but Cedes Viewers From Season Premiere
CBS News’ “60 Minutes” shed some of the viewers it snared during its much-anticipated Season 59 debut as it grappled with the effects of CBS’ football programming on its audience, even as it notched a gain in audience compared to its year-earlier performance. The audience for the second telecast of the venerable newsmagazine rose 5% […]
Nancy Meyers’ Daughter Just Launched a Target Home Collection That Looks Straight Out of One of Her Mom’s Movies
Nancy Meyers has spent decades making audiences covet the kitchens, living rooms and impossibly cozy interiors in her movies. Now, her daughter is making that aesthetic a little easier to bring home. Target has teamed with Annie Meyers-Shyer, the author and creator behind @ThisOakHouse, for a new home collection under its Threshold label, featuring vintage-inspired […]
Dolly Parton Reportedly Secretly Traveled to Germany for Experimental Cancer Treatment
Dolly Parton reportedly traveled overseas for an experimental cancer treatment about a year before her passing. The legendary country singer, […] The post Dolly Parton Reportedly Secretly Traveled to Germany for Experimental Cancer Treatment appeared first on Just Jared - Celebrity News, Entertainment News & Photos.
Presley Gerber's Ex Lexi Wood Says He "Fought So Hard for His Life"
Lexi Wood is remembering Presley Gerber's light. The Summer House alum, who dated the model in 2022, spoke out after his heartbreaking death. "It’s hard to put into words what it means to lose...
Recommended
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.